Antiviral drug (project company Liperon, LLC)
(trade name – Camphecin®)
Camphecin® is the first inhibitor of specific viral protein hemagglutinin in the market (hemagglutinin is one of the main proteins of influenza virus and a more promising drug target than neuramidase targeted by the existing drugs).
Patent profile: patented in Russia
Indications for use:
– prevention and treatment of flu, acute respiratory infection, mixed infections (including flu + COVID)
Main advantages:
– direct action on the virus (unlike immunostimulators and interferon inducers);
– high efficacy against a wide range of influenza viruses, including the most dangerous subtypes A(H1N1), A(H3N2), A(H5N2) and others;
– efficacy confirmed in preclinical studies in a model of lethal influenza pneumonia and comparable to oseltamivir (Tamiflu) – the “gold standard” of influenza therapy;
– efficacy against Tamiflu-resistant strains of influenza virus;
– high safety in therapeutic doses, it can potentially be used in pediatrics and in weakened patients (including the elderly);
– binding to the virus target at the site least susceptible to mutations, which reduces the risk of resistance to the drug to a statistically unlikely level and prolongs the “lifecycle” of the drug on the market;
– simple substance synthesis technology (only 1 stage) using standard equipment, available raw materials, absence of organic solvents optimizes production cost and increases the sales margin of the drug.
– proprietary synthesis of the pharmaceutical substance and lack of analogs will delay and complicate the launch of generic drugs in the Russian Federation (after the expiration of patent protection) and in other markets.
Current status: Substance and dosage form are developed. Pilot batches for preclinical and clinical studies are produced. Preclinical studies are completed. Permission of the Ministry of Health of the Russian Federation for Phase I clinical trials has been granted.
Video: https://youtu.be/ltKnAE24rwI